unrelated donors. [1] [2] [3] [4] [5] This effect is attributable, at least in part, to increased acute and chronic graft-versus-host disease (GVHD) in recipients of mismatched BMT. However Eleven patients with high-risk hematologic malignancy received cryopreserved but otherwise unmanipulated the magnitude of this effect is such that, in some reports of related donor BMT for leukemia, mismatch by a single blood cell transplants (BCT) from partially mismatched family members in whom progenitor cells had been antigen results in similar disease-free survival to fully matched transplants. 1, 4, 6 A number of recent studies indimobilized by G-CSF. Donors were mismatched by up to one antigen in the GVH direction and up to three cates that transplants using mobilized peripheral blood progenitor cells (blood cell transplants, BCT) may have some antigens in the rejection direction. Outcomes were compared with those of 22 patients receiving BCT from fully advantages over BMT, particularly that of accelerated engraftment. [7] [8] [9] [10] [11][12][13][14][15][16] Although there was concern that the relamatched donors. Two mismatched patients died without engraftment on day 21 and 32. One had rejected bone tively high number of infused lymphocytes might result in unacceptably severe acute GVHD this has not been seen in marrow from the same donor, the other was mismatched by two antigens in the rejection direction and the allogeneic BCT reported so far, most of which have been from fully matched family members. Information is received the lowest dose of CD34 ؉ cells. Median time to granulocyte engraftment was 21.5 (range 16-33) days limited concerning the feasibility of partially mismatched transplants using blood cells without T cell depletion. We for the mismatched group compared with 16 (11-28) days for the matched group (P = 0.01). No correlation have compared the outcomes of such transplants for highrisk leukemia patients with those of fully matched BCT. was found between CD34
862 Table 1 Comparison of pretransplant characteristics of BCT patients after early experiences with graft failure we attempted to MDS = myelodysplastic syndrome; ALL = acute lymphoblastic leukemia; CML = chronic myelogenous leukemia; CLL = chronic lymphocytic harvest more than 5 × 10 6 CD34 + cells/kg for BCT misleukemia; CR = complete remission; Bu = busulfan; CY = cyclomatched by more than one antigen in the rejection direcphosphamide; TBI = total body irradiation.
tion. T cells (carrying the CD3 antigen) were also counted in the apheresis product. In order to ensure that a similarly treated product was complement-dependent microcytotoxicity test. HLA-DR typing employed Dynabead-purified B cells (Dynal Inc, given at a consistent time to all recipients the cells were cryopreserved in a controlled-rate freezer using 10% Success Lake, NY, USA) in a microcytotoxicity assay. DNA for molecular typing was extracted from mononuclear DMSO as a cryoprotectant and stored in liquid nitrogen. cell lysates. Cells were heated then treated with proteinase K. DRB1 alleles recognized by the WHO Nomenclature Treatment of recipients Committee for Factors of the HLA System were typed by amplification of the second exon of DRB1 followed by A variety of cytotoxic conditioning therapies was given according to institutional protocols (Table 1) . Some were sequence-specific oligonucleotide probe hybridization. 17 standard protocols for the relevant disease or, in the case of second transplants, chosen to differ from the first conCollection and evaluation of blood cells from donors ditioning therapy. Two patients, mismatched by two and three antigens in the rejection direction, received a combiDonors were family members aged 11-51 years (median 36). Relationships to recipients were siblings (five), halfnation of cyclophosphamide, thiotepa and single fraction TBI, a variant of the protocol recently described by Aversa siblings (one), parents (four) and children (one). Donors were treated with rh-G-CSF (Amgen, Thousand Oaks, CA, et al. 18 Antithymocyte globulin (ATG) (Upjohn, Don Mills, Ontario, Canada) 90 mg/kg was given as additional GVHD, and disease-free survival in the two groups. The rank-sum test was employed for comparison of times to immunosuppression to five recipients of mismatched BCT. Two had rejected a prior BMT and three were mismatched onset of acute GVHD. The ANOVA test was used to compare doses of CD3 + and CD34 + cells. Analysis was perforby two or three antigens in the rejection direction.
On the day of BCT the leukapheresis product was thawed med on a Macintosh computer using Stata software (Stata Corp, College Station, TX, USA). and infused rapidly. No protective isolation was used. 19 The acute GVHD prophylaxis protocol included CsA orally or intravenously twice daily to maintain blood levels between 250 and 400 mol/l. Methotrexate was given in doses of Results 15 mg/m 2 on day 1 and 10 mg/m 2 on days 3, 6 and 11. Folinic acid 5 mg was started 24 h after each dose of MTX Harvest of CD34 + cells and continued every 6 h until 12 h before the next dose.
20
The schedule was modified in two patients with renal failWhen donors for both mismatched and matched patients ure and one with pleural effusion, all in the matched group.
are considered, in 30 of 33 the target yields of CD34 + cells They received 15 mg doses starting 6 h after each MTX were exceeded during single harvests of 2-4 h with prodose. Routine antifungal prophylaxis was not used. Growth cessed blood volumes of 5. /kg. ations at 3 months for surviving patients or as clinically indicated. Granulocyte engraftment was defined as a count Engraftment of у0.5 × 10 9 /l. The platelet count needed to be above 20 × 10 9 /l without transfusion for 3 days. Patients were conOne patient had no evidence of engraftment when she died sidered inevaluable for engraftment of a cell line if they on day 21. She had previously rejected a BMT from a onedied by day 21 without recovery of that cell line. Platelet antigen mismatched son and had multiple HLA antibodies engraftment was evaluated up to day 42, later recovery was in addition to donor-specific antibodies. A second patient, scored as a failure to engraft.
mismatched by two antigens in the rejection and one in the The source of engrafted cells in peripheral blood and/or GVH direction, had failed to engraft whe she died of sepsis bone marrow was confirmed by comparison of donor and at day 32 despite having developed acute GVHD on day recipient polymerase chain reaction (PCR) amplified and 9. She received the lowest CD34
+ cell dose at radiolabeled DNA fragments resolved on polyacrylamide 2.6 × 10 6 /kg (Table 2 ). gels and detected by autoradiography. 21 Granulocytes engrafted in the remaining nine of 11 mismatched patients and in all 22 matched patients. One recipiGraft-versus-host disease ent of a mismatched BCT receiving G-CSF was excluded from the comparison of engraftment times. The median Acute GVHD was graded according to standard criteria and time to engraftment was 21.5 (range 16-33) days for the patients were only considered evaluable if they survived mismatched group compared with 16 (11-28) days for the beyond day 21. 22 Only cases of clinical and/or histological matched group (P = 0.01, Figure 1 ). Even when nonacute GVHD occurring before day 100 were classified as engrafting patients are excluded the difference in the rate acute GVHD. Treatment was with methylprednisolone 1.5-of engraftment remains significant (P = 0.05). 12 mg/kg i.v. twice daily with dose tapering according to Platelets engrafted within 42 days in 6/11 mismatched clinical response.
patients for whom the rate of engraftment (11-33 days, Patients alive beyond day 60 were considered evaluable median 16) was similar to that observed in 20/22 matched for chronic GVHD.
patients who engrafted (11-34 days, median 15). There was no correlation between CD34 + cell doses and Informed consent granulocyte or platelet recovery in either patient group.
Donors, recipients and parents where appropriate were fully informed about the investigational nature of the treatment.
Source of engrafted cells The protocol and consent forms were approved by the University of Calgary Conjoint Medical Ethics Committee.
In the one patient with CML in accelerated phase rejecting a BCT as a second transplant, blood and marrow at day 21 were positive by PCR for both recipient cells and the bcrStatistical analysis abl breakpoint with no donor material detectable. Donor origin of marrow and/or peripheral blood cells was conThe distributions of time to platelet and granulocyte recovery were compared using the Wilcoxon test. The log-rank firmed in the remaining BCT recipients who survived 100 days. test was used to compare the incidence of acute and chronic
Relapse
One recipient of mismatched BCT was positive by PCR for both recipient cells and the bcr-abl breakpoint when she died on day 21. Eight matched patients had persistent (three) or relapsed (five) disease. Because of the heterogeneity of diagnosis a statistical comparison of relapse rates was not considered meaningful.
Non-relapse mortality
In the mismatched BCT group two patients died of graft matched group were attributed to acute GVHD (with aspergillus at autopsy), chronic GVHD, pneumonia and cerebral hemorrhage.
Graft-versus-host disease
All scheduled doses of MTX were administered. We treated Survival and quality of life any grade of acute GVHD with systemic steroids. The Disease-free survival at 1 year was similar in the two incidence of grade II-IV acute GVHD differed significantly groups at 55% (95% Cl 23-78%) for mismatched and 50% between the groups at 73% (95% Cl 43-95%, 7/10 patients) (95% Cl 27-68%) for matched BCT (Figure 4 ). With a for mismatched vs 28% (95% Cl 11-53%, 6/22 patients) median follow-up of survivors of 16 months (range 9-34 for matched BCT (P = 0.001, Figure 2a ). Corresponding months) one of six recipients of mismatched BCT and two figures for grade III-IV GVHD were 38% (95% Cl 12-of 10 recipients of matched BCT have Karnofsky status 80%, 2/22 patients) and 12% (95% Cl 5-65%, 3/10 limited to 70% by chronic GVHD. The remainder are funcpatients), respectively (P = 0.04). The median time of onset tioning at 80-100%. was 12 days in the mismatched vs 30 days in the matched patients (P = 0.2).
The incidence of chronic GVHD at 18 months is 100% Discussion (95% Cl 48-100%) in recipients of mismatched BCT and 78% (95% Cl 50-95%) in the matched BCT group (P = 0.01, Figure 2b) .
Most published reports of allogeneic BCT, predominantly from fully matched donors, do not indicate a significantly There was no relationship of CD3 + cell doses to acute GVHD in the matched group (Figure 3) . Because of small greater risk of acute GVHD than BMT although one series does indicate a trend in this direction. 13 The current study numbers it was impossible to determine a relationship in the mismatched patients as only one patient had grade 0 and indicates that BCT from mismatched donors results in significantly more acute GVHD than from matched donors. In grade I GVHD, respectively. Among patients with grade II-IV GVHD higher CD3 + doses were given to the misaddition, the risk of chronic GVHD was very high in both groups with all survivors of mismatched BCT developing matched patients (706 ± 121 × 10 6 /kg vs 361 ± 46 × 10 6 /kg, P = 0.02). Because of the limited follow-up and the high this complication. However, we have no evidence in this small study that overall quality of life is significantly worse proportion of mismatched patients developing chronic GVHD, the influence of CD3 + cell doses cannot be deterfor mismatched BCT recipients. There are at least two recent reports indicating a high rate of chronic GVHD in mined. Analysis of CD34 + cell dose showed no effect on engraftment in our recipients of matched BCT. This finding is consistent with another recent report of allogeneic BCT. 9 It seems that recipients of autologous PBSC do not show further acceleration of engraftment at CD34 + cell doses above 2-3 × 10 6 /kg and it may be that cell doses given to our matched BCT patients were all above such a threshold level.
26 Two of our mismatched receipients failed to engraft. One was at especially high risk, given rejection of a prior BMT and the presence of donor-specific antibodies. Coincidentally, the second patient received the lowest CD34 + cell dose at 2.6 × 10 6 /kg. Körbling et al 8 reported a patient mismatched by one antigen who failed to engraft with 8.6 × 10 6 /kg CD34 + cells. One cannot say whether augmented cell doses or conditioning would have facili- Despite the trend to higher procedure-related mortality in the mismatched patients, disease-free survival is similar of 28 (79%) by Bacigalupo et al 15 developed chronic GVHD. Thus, if we include the current study, three of the because of more relapsed and persistent malignancy in matched BCT recipients. This study involves small nummore mature reports are now suggesting that BCT may indeed result in more GVHD than BMT. Confirmation of bers of patients and the groups differed somewhat with respect to diagnosis and other characteristics such as age. It this suspicion, and assessment of any impact on diseasefree survival, will need to await the results of controlled would therefore be premature to speculate that mismatching contributes to an enhanced graft-versus-malignancy effect studies.
The observation that T cell dose did not influence GVHD which compensates, at least in part, for higher transplantrelated mortality in these patients. 27 This may, however, be in the matched patients is consistent with other reports of both BMT and BCT indicating no influence of dose above the explanation for similar observations in large series of related and unrelated BMT and also where BMT from these a threshold level. 9, 23, 24 Increased GVHD in recipients of mismatched BCT is likely related to incompatibility rather two sources are compared. 1, 3, 6 In particular, although increasing disparity tends to result in more GVHD, misthan T cell dose and is consistent with the findings of a number of large studies of BMT from related and unrelated matching by a single antigen does not necessarily result in poorer survival in some patient groups, for example donors. [1] [2] [3] [4] [5] Even genotypically distinct transplants with no mismatch in the GVH vector (four in this series) would be younger patients or those in remission when transplanted. 5, 6 Despite the small patient numbers our findings have more likely to be mismatched for molecular variants of HLA antigens contributing to GVHD. important clinical implications. First, they demonstrate that such partially mismatched BCT could be further explored Studies of BMT have also indicated that failure to engraft is more frequent in mismatched patients. 2, 25 Animal experias one option when a fully matched family donor is not available. It is noteworthy that in the time frame of this ments have shown that progenitor cell dose and intensity of conditioning therapy may offset this effect to some extent. 25 study a third of our BCT for high-risk disease was from Marrow Transplant 1996; 17: 703-708. 14 Majolino I, Saglio G, Scime R et al. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
